4BASEBIO UK SOCIETAS - Asset Resilience Ratio

Latest as of December 2024: 0.50%

4BASEBIO UK SOCIETAS (4BB) has an Asset Resilience Ratio of 0.50% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of 4BASEBIO UK SOCIETAS for a breakdown of total debt and financial obligations.

Liquid Assets

GBX225.00K

≈ $27.38 USD Cash + Short-term Investments

Total Assets

GBX44.73 Million

≈ $5.44K USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how 4BASEBIO UK SOCIETAS's Asset Resilience Ratio has changed over time. See 4BB net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down 4BASEBIO UK SOCIETAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4BASEBIO UK SOCIETAS (4BB) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX225.00K	0.5%
Total Liquid Assets	GBX225.00K	0.50%

Asset Resilience Insights

Limited Liquidity: 4BASEBIO UK SOCIETAS maintains only 0.50% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

4BASEBIO UK SOCIETAS Industry Peers by Asset Resilience Ratio

Compare 4BASEBIO UK SOCIETAS's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for 4BASEBIO UK SOCIETAS (2019–2024)

The table below shows the annual Asset Resilience Ratio data for 4BASEBIO UK SOCIETAS.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.50%	GBX225.00K ≈ $27.38	GBX44.73 Million ≈ $5.44K	-1.48pp
2023-12-31	1.98%	GBX236.00K ≈ $28.71	GBX11.92 Million ≈ $1.45K	-0.07pp
2022-12-31	2.05%	GBX240.00K ≈ $29.20	GBX11.69 Million ≈ $1.42K	+0.50pp
2021-12-31	1.55%	GBX228.00K ≈ $27.74	GBX14.70 Million ≈ $1.79K	+0.32pp
2020-12-31	1.23%	GBX219.00K ≈ $26.65	GBX17.81 Million ≈ $2.17K	-15.74pp
2019-12-31	16.97%	GBX196.00K ≈ $23.85	GBX1.16 Million ≈ $140.53	--

pp = percentage points

About 4BASEBIO UK SOCIETAS

LSE:4BB UK Biotechnology

Market Cap

$951.45K

GBX7.82 Billion GBX

Market Cap Rank

#30242 Global

#809 in UK

Share Price

GBX505.00

Change (1 day)

+0.00%

52-Week Range

GBX474.00 - GBX1125.00

All Time High

GBX1820.00